Stock Price Quote

DISHMAN CARBOGEN AMCIS LTD.

NSE : DCALBSE : 540701ISIN CODE : INE385W01011Industry : Pharmaceuticals & DrugsHouse : Dishman Pharma
BSE221.251.95 (+0.89 %)
PREV CLOSE ( ) 219.30
OPEN PRICE ( ) 214.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 32616
TODAY'S LOW / HIGH ( )213.45 224.15
52 WK LOW / HIGH ( )113.25 282.95
NSE221.051.5 (+0.68 %)
PREV CLOSE( ) 219.55
OPEN PRICE ( ) 217.00
BID PRICE (QTY) 221.05 (53)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 383540
TODAY'S LOW / HIGH( ) 213.40 224.15
52 WK LOW / HIGH ( )113.1 283
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 2007
Management Info
Janmejay R Vyas - Chairman Arpit J Vyas - Managing Director
Registered Office

Address Dishman Corporate House,Iscon - Bopal Road,Ambli,
Ahmedabad,
Gujarat-380058

Phone 02717 420102 / 124

Email dishman@dishmangroup.com

Website www.dishmangroup.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

03Feb Dishman Carbogen Amcis informs about d
Dishman Carbogen Amcis has informed that it attached the disclosure purs..
22Sep Dishman Carbogen Amcis informs about c
Dishman Carbogen Amcis has informed that as per Code of Conduct for prev..
15May Dishman Carbogen Amcis informs about b
Pursuant to Regulation 29 and 50 of SEBI (Listing Obligations and Disclo..
17Feb Dishman Carbogen Amcis moves up as its
Dishman Carbogen Amcis is currently trading at Rs. 103.30, up by 1.90 po..
16Feb Dishman Carbogen Amcis’ arm completes
Dishman Carbogen Amcis’ wholly owned subsidiary--Carbogen Amcis AG has s..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-181.8-588.699999999999
Gross Profit -270.8 -961.999999999999
Operating Profit 162.8599.200000000001
Net Sales 868.24025.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

PROMOTERS 59.32%
MUTUAL FUNDS/UTI 3.45%
NON-INSTITUTION 28.39%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Dishman Carbogen Amcis Ltd.

Dishman Carbogen Amcis Ltd. was incorporated in the year 2007. Its today's share price is 221.25. Its current market capitalisation stands at Rs 3468.83 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4025.5 Cr and Total Income of Rs.4547.1 Cr. The company's management includes Shrima G Dave, Maitri Mehta, Rajendra S Shah, Subir Kumar Das, Arpit J Vyas, Deohooti J Vyas, Janmejay R Vyas.

It is listed on the BSE with a BSE Code of 540701 , NSE with an NSE Symbol of DCAL and ISIN of INE385W01011. It's Registered office is at Dishman Corporate House,Iscon - Bopal Road,AmbliAhmedabad-380058, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Haribhakti & Co LLP, Kunte & Associates., TR Chadha & Co LLP, VD Shukla & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.